Status:
COMPLETED
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
Lead Sponsor:
GE Healthcare
Collaborating Sponsors:
i3 Statprobe
Covance
Conditions:
Brain Fibrillarab Levels
Eligibility:
All Genders
55+ years
Phase:
PHASE3
Brief Summary
To determine the level of association between quantitative regional estimates of brain uptake of \[18F\]flutemetamol and quantitative immunohistochemical regional estimates of brain levels of amyloid ...
Eligibility Criteria
Inclusion
- The subject has a short life expectancy (approximately 1 year or less) as estimated by the Investigator.
- The subject is 70 years of age or older if cognitively normal, or 55 years of age or older if terminal because of dementia.
- The subject's general health is adequate to undergo the study procedures.
Exclusion
- The subject has a contraindication for PET.
- The subject has a known or suspected hypersensitivity/allergy to \[18F\]flutemetamol or to any of the excipients.
- The subject is unable to tolerate or cooperate with study procedures.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT01165554
Start Date
May 1 2010
End Date
November 1 2011
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GE Healthcare
Princeton, New Jersey, United States, 08540